Blood
Audio Summaries

From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma

Mar 23, 2026

The authors examine the evolving treatment landscape for relapsed or refractory large B-cell lymphoma (R/R LBCL) in light of recent advancements in cellular therapies, bispecific antibodies, and next-generation antibody-drug conjugates. They aim to address the challenges posed by trial design and therapeutic sequencing, emphasizing the need for improved evidence infrastructure and biologically rational treatment pathways to ensure equitable access to effective therapies for all patients. The paper highlights the urgency of adapting clinical trials to keep pace with rapid innovations in treatment options.

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML

Mar 18, 2026

The authors investigate how inhibition of the lysine acetyltransferase (KAT) activity of p300/CREBBP affects transcription in acute myeloid leukemia (AML). They find that this inhibition paradoxically enhances transcription by promoting cooperative transcription factor assembly and increasing H3K27 acetylation at specific regulatory elements, particularly those associated with interferon-stimulated genes. Their findings suggest a novel therapeutic strategy that combines KAT inhibition with interferon-alpha to drive AML cell death and improve treatment outcomes.

Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models

Mar 18, 2026

The authors investigate the efficacy of ziftomenib, a selective small molecule inhibitor targeting the menin-KMT2A interaction, in treating acute leukemia characterized by KMT2A rearrangements and NPM1 mutations. They demonstrate that ziftomenib effectively inhibits leukemia cell proliferation and induces differentiation in preclinical models, including those with menin mutations associated with resistance to other inhibitors. The study highlights ziftomenib's potential as a therapeutic option for acute leukemia patients with specific genetic alterations, supported by its recent FDA approval for NPM1-mutated acute myeloid leukemia.

Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy

Mar 18, 2026

The authors aimed to determine the efficacy of different graft-versus-host disease (GvHD) prophylaxis strategies in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) for patients with acute myeloid leukemia or myelodysplastic syndromes. In a randomized phase III trial involving 407 patients, they found that low-dose ATG combined with PTCy, standard-dose ATG, and PTCy alone had similar effectiveness in preventing grade II-IV acute GvHD and comparable survival rates, although the combination regimen showed significantly better neutrophil and platelet recovery.

Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia

Mar 18, 2026

The authors investigate the differential effects of ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) on fracture risk and bone metabolism in patients with iron deficiency anemia. Their findings reveal that FCM is associated with a significantly higher incidence of osteomalacia and fractures compared to FDI, which they attribute to FCM's impact on bone formation and mineral metabolism, as demonstrated in both patient cohorts and mouse models. The study highlights the potential mechanisms by which FCM treatment may impair bone health, suggesting a need for caution in its use.

A Dried Platelet-Derived Biologic for Blood-Brain Barrier Repair and Hemorrhage Control Following TBI in Mice

Mar 17, 2026

The authors investigate the therapeutic potential of a freeze-dried platelet-derived biologic (FDPlts) for addressing acute complications of traumatic brain injury (TBI), specifically targeting cerebral edema and intracranial hemorrhage. Their findings indicate that FDPlts significantly reduce post-TBI hemorrhage, restore cerebral vascular perfusion, and enhance blood-brain barrier stability, suggesting a novel approach to promote vascular repair and neuroprotection following TBI. The study highlights the role of Angiopoietin-1 in mediating these protective effects, marking a significant advancement in TBI treatment strategies.

Clinical Spectrum of Hereditary Hemorrhagic Telangiectasia: Data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)

Mar 17, 2026

The authors aimed to characterize the clinical spectrum of hereditary hemorrhagic telangiectasia (HHT) using data from the Comprehensive HHT Outcomes Registry of the United States (CHORUS). Their findings reveal a significant delay in diagnosis, with many patients experiencing severe bleeding and complications, such as anemia and thromboembolism, highlighting the need for improved awareness and management of this condition. The study underscores the high burden of morbidity associated with HHT, emphasizing the importance of early detection and intervention.

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study

Mar 17, 2026

The authors aimed to characterize the clinicopathological features and prognostic factors of immunodeficiency-associated primary CNS lymphoma (ID-PCNSL) through an international retrospective study involving 308 cases. They found that immune reconstitution and rituximab-methotrexate-based chemotherapy improved response rates and survival, while age, Karnofsky Performance Status, and EBV positivity were identified as significant prognostic factors. Additionally, they developed a prognostic score to better stratify patients based on these variables, enhancing management strategies for ID-PCNSL.

Defective cerebrovascular development in mice lacking TFPI is restored by activated protein C

Mar 13, 2026

The authors investigate whether excess activated protein C (aPC) can rescue cerebrovascular defects in mice lacking Tissue Factor Pathway Inhibitor (Tfpi-/-), which typically leads to embryonic lethality due to thrombin overproduction. They find that while aPC reduces glomeruloid body numbers and improves survival, it does not fully correct all cerebrovascular issues, indicating that TFPI plays a critical and non-redundant role in embryonic angiogenesis and thrombin regulation. The study highlights the complex interplay between coagulation factors and vascular development during embryogenesis.

TMEM187 is a novel modulator in the regulation of erythropoiesis

Mar 13, 2026

The authors investigate the role of TMEM187 in erythropoiesis, specifically its function as a negative regulator of red blood cell production and iron uptake. They demonstrate that the absence of TMEM187 accelerates erythropoiesis and alters iron recycling mechanisms, leading to premature cell maturation and increased susceptibility to phagocytosis. Their findings highlight a novel pathway through which TMEM187 modulates erythroid differentiation and maturation by interacting with RAB11 to regulate transferrin receptor recycling.